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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of rehabilitation therapies for people with CIP and CIM.
The primary objective is to assess the effectiveness of such interventions in improving daily activities such as walking, bathing, dressing
and eating.
Secondary objectives are to assess effects on muscle strength and quality of life, and to assess adverse effects of rehabilitation.
B A C K G R O U N D
Description of the condition
Critical illness myopathy (CIM) and polyneuropathy (CIP) are
common complications of critical illness that frequently occur
together. Both conditions cause weakness of limb and respiratory
muscles, which increase morbidity and impede recovery.
CIP is a distal axonal sensory-motor polyneuropathy, whichmeans
that multiple nerves that control movement and carry sensation
are affected. CIP presents as limb and respiratory muscle weak-
ness (Fan 2012; Lacomis 2000), and is closely associated with a
failure to wean patients from mechanical ventilation (Fan 2012;
Latronico 2011). The diagnostic criteria for CIP as a dysfunction
of (multiple) peripheral nerves are, according to Bolton 2005 and
Latronico 2011, as follows.
1. The individual is critically ill (multi-organ dysfunction and
failures).
2. The individual has limb weakness, or is difficult to wean
from a ventilator (after exclusion of non-neuromuscular causes
such as heart and lung disease).
3. There is electrophysiological evidence of axonal motor and
sensory polyneuropathy.
4. There is an absence of a decremental response on repetitive
nerve stimulation (Latronico 2011).
A definite diagnosis of CIP, according to Bolton 2005 and
Latronico 2011, is established if all four criteria are fulfilled. A
probable diagnosis of CIP is established if criteria one, three and
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four are fulfilled.
CIM is a primary myopathy (that is, a muscle disorder) that is
not secondary to muscle denervation, and which has characteristic
electrophysiological andmorphological changes (Latronico 2011).
The diagnostic criteria for critical illness myopathy are, according
to Latronico 2011, as follows.
1. The individual is critically ill (multi-organ dysfunction and
failures).
2. The individual has limb weakness, or is difficult to wean
from a ventilator (after exclusion of non-neuromuscular causes
such as heart and lung disease).
3. Compound muscle action potential (CMAP) amplitudes
less than 80% of the lower limit of normal are recorded in two or
more nerves without conduction block.
4. Sensory nerve action potential amplitudes are more than
80% of the lower limit of normal.
5. Needle electromyography has detected:
i) short duration, low-amplitude motor unit potentials
with early or normal full recruitment, with or without
fibrillation potentials in conscious and cooperative patients; or
ii) increased CMAP duration or reduced muscle
membrane excitability on direct muscle stimulation in non-
cooperative patients.
6. An absence of a decreasing response on repetitive nerve
stimulation.
7. Muscle histopathological findings of primary myopathy (for
example, myosin loss or muscle necrosis).
Fulfillment of all criteria establishes a definite diagnosis of CIM
(Latronico 2011). Fulfillment of criteria one and three to six estab-
lishes a probable diagnosis of CIM. For our review we will apply
these definitions of CIP and CIM.
The pathophysiology of CIP and CIM is complex and remains
unclear (Hermans 2008). The development of CIP and CIM is
thought to involve electrical, microvascular, metabolic and bioen-
ergetic pathophysiological mechanisms (see Hermans 2008 for a
good overview). Crucial risk factors for CIP and CIM are sepsis,
systemic inflammatory response syndrome, and multiple organ
failure (Hermans 2008).
Exact numbers and rates of CIP and CIM are not well established
because of variations in the patient population, in risk factors and
in the diagnostic and assessment criteria used. In people receiv-
ing mechanical ventilation or with an increased risk of developing
multi-organ failure, the risk of developing CIP or CIM is about
30% and the risk increases up to 50% in people with acute respi-
ratory distress syndrome (Hermans 2008). The risk of developing
CIP or CIM is associated with a lengthy (more than one week)
stay in the intensive care unit (ICU), multi-organ failure (with
or without sepsis) and systemic inflammatory response syndrome
(Bercker 2005; Hermans 2008). A systematic review estimated
the incidence of CIP and CIM at 46% (95% CI 43% to 49%)
among adults who had remained in the ICU for more than two
weeks, who were receiving mechanical ventilation and had sepsis
or multi-organ failure (Stevens 2007).
The short- and long-term impact of CIP and CIM are well de-
scribed (Herridge 2011; Ohtake 2012;Hermans 2008). Themus-
cle weakness associatedwith these conditions can prolong the need
for supported ventilation and delay weaning from a ventilator. In
turn, this can mean a longer stay in the ICU and in hospital, and
slower rehabilitation (Hermans 2008; Zanni 2010). Although full
recovery has been reported in approximately 50% of people with
CIM/CIP, improvement is related to the severity of the condition.
People who are only mildly affected can recover within weeks, but
those with more severe weakness may take months to improve, or
in some cases, remain severely affected with partial or no recov-
ery (Hermans 2008). Clinical and neurophysiological signs may
remain for up to five years after discharge from hospital and may
lead to long-term paresis or paralysis (Herridge 2011).
Generalised weakness syndromes such as CIP and CIM are a ma-
jor cause of chronically impaired motor function that can affect
activities of daily living and participation. Physical rehabilitation
of those affected is therefore of great importance and interest.
Description of the intervention
In the last five years, research has suggested that physical rehabilita-
tionmay improve activities in people with CIP and CIM (Norton-
Craft 2012; Connolly 2012; Ohtake 2012; Bemis-Dougherty
2012; Fan 2012). Rehabilitation interventions include physical
and occupational therapy techniques, such as stretching, strength
training and mobility training (for example, training in dress-
ing and transfers, or to improve balance, sit-to-stand, and walk-
ing) (Burtin 2009; Hanekom 2011; Herridge 2011; Fan 2012;
Norton-Craft 2012). There has, however, been no Cochrane re-
view of the available literature on the efficacy and acceptability of
physical rehabilitation approaches to treat people who have devel-
oped CIP and CIM.
Why it is important to do this review
Advances in medical care, increased survival rates and better di-
agnosis of CIP and CIM, as well as the availability of more effec-
tive therapy, have highlighted the need for and potential value of
rehabilitation for people with critical illness. However, although
rehabilitation guidelines give recommendations, there is limited
evidence on which to base practice (Connolly 2012). People with
ICU-acquired weakness may be most likely to benefit from ongo-
ing rehabilitation (Connolly 2012). A recent special issue in the
journal Physical Therapy underlined the importance of the topic;
the authors concluded that physical rehabilitation approaches for
improving activities after CIP/CIM showed some promising signs
of effectiveness (Bemis-Dougherty 2012;Norton-Craft 2012), but
there was a need for more evidence to provide clear guidelines.
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In addition to the question of whether physical rehabilitation in
general is beneficial, it is still unclear which specific rehabilitation
approaches are effective, and the most appropriate frequency and
intensity with which to apply them in practice (Connolly 2012).
There is currently no Cochrane systematic review in this area. We
therefore aim, in this Cochrane review, to compile and assess all the
available literature about the effectiveness and safety of physical
rehabilitation in CIP and CIM, so as to provide comprehensive,
up-to-date evidence on which to base clinical practice.
O B J E C T I V E S
To assess the effects of rehabilitation therapies for people with CIP
and CIM.
The primary objective is to assess the effectiveness of such inter-
ventions in improving daily activities such as walking, bathing,
dressing and eating.
Secondary objectives are to assess effects on muscle strength and
quality of life, and to assess adverse effects of rehabilitation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill consider randomised controlled trials (RCTs), quasi-RCTs
and randomised controlled cross-over trials. Quasi-RCTs are trials
in which the method used to allocate participants to interventions
is not truly random (for example, using date of birth or hospital
number).
Types of participants
We will include participants aged 18 and over in both inpatient
and outpatient settings, who have generalised weakness syndrome
and a confirmed or probable diagnosis of CIP or CIM. We will in-
clude studies with mixed populations of people with neurological
conditions if we are able to obtain the data for participants with
generalised weakness syndrome due to CIP or CIM.
Types of interventions
We will include all trials of CIM and CIP that compare any re-
habilitation intervention, such as physiotherapy or occupational
therapy, or both, with any other interventions for improving func-
tion and activity. Possible and typical interventions in this review
might be cycling, sit-to-stand training, walking and gait training,
and neuromuscular electrical stimulation to lower extremity mus-
cle groups.
We will include all studies of inpatient and outpatient physical
rehabilitation in the acute and chronic phase that compare two or
more interventions; for example, neuromuscular electrical stimu-
lation versus usual therapy, or neuromuscular electrical stimula-
tion versus another active intervention (such as muscle strength
training, dressing exercises, or gait training). The intervention and
control group must have received the same (standard) medication
or rehabilitation. We will therefore allow co-interventions as long
as they are provided in the same amount to all randomised partic-
ipants.
Types of outcome measures
The time frame for outcome measurement will be immediately
after the intervention and at follow-up one year later.
Primary outcomes
Our primary outcome measure will be activities (for example, mo-
bility, walking, transfers, and self care), as measured by validated
outcome tools.
Measurement tools will be the Functional Independence Measure
(FIM) (Dodds 1993), the Barthel Index (Mahoney 1965) and
other validated scales for the ICU such as the Functional Status
Score for ICU (FSS-ICU) (Zanni 2010), the Acute Care Index
of Function (ACIF) (Roach 1988), the Physical Function Out-
come Measure (PFIT) (Skinner 2009), or other validated mea-
sures. Measures of walking ability will be gait speed in m/s and
six-minute walking distance (Norton-Craft 2012).
If studies use multiple scales to measure our primary outcome, we
will, in the absence of our preferred measures, list and report all
scales and measures used in these studies.
Secondary outcomes
We will report the following secondary outcomes.
1. Muscle strength (as measured by, for example, the Medical
Research Council (MRC) Scale for Muscle Strength (Fan 2012)).
2. Quality of life measured by validated measures, such as the
Short Form-36 Health Survey (SF-36) (Skinner 2011), the
RAND-36 (Kaarlola 2006), or the Assessment of Quality of Life
(AQol) Utility Instrument (Denehy 2008).
3. Frequency of adverse effects as a result of the intervention.
We will also report all serious adverse events, defined as those
events that are life-threatening, require prolonged hospitalisation,
or are fatal. We will report adverse events that occur during the
intervention or at less than 12 months after study onset.
We will report any information on costs in the ’Discussion’.
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Outcomes for inclusion in a ‘Summary of findings table’
We will use GRADEpro (GRADEpro 2008) software and create
a ’Summary of findings’ table with the following outcomes: ac-
tivities, muscle strength, quality of life and adverse effects. Time
points for all outcomes in the ’Summary of findings’ table will be
immediately after the intervention and at follow-up one year later.
We will use the five GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of a body of evidence (studies that con-
tribute data for the prespecified outcomes). We will use methods
and recommendations described in Chapter 12 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will justify all decisions to down- or up-grade the quality of
evidence using footnotes.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Neuromuscular Disease Group Spe-
cialized Register, CENTRAL (The Cochrane Library current is-
sue), MEDLINE (1966 to present), EMBASE (1980 to present),
CINAHL (from 1982), and the Physiotherapy Evidence Database
(PEDro, http://www.pedro.org.au/). We will use the search strat-
egy in Appendix 1 to search MEDLINE and will modify it for the
other databases. There will be no language restrictions.
We will search ClinicalTrials.gov (http://clinicaltrials.gov/),
the World Health Organization International Clinical Tri-
als Registry Platform (ICTRP) portal (http://www.who.int/
ictrp/en/) and the European Union Clinical Trials Register (
www.clinicaltrialsregister.eu) for ongoing trials and further data
about included studies.
Searching other resources
We will review the bibliographies of any identified RCTs and con-
tact the authors and known experts in the field to identify addi-
tional published or unpublished data.
Data collection and analysis
Selection of studies
Two review authors (JM and MP) will independently select the
eligible trials based on the predefined selection criteria and will
resolve disagreement through discussion with the other review au-
thors. If we need further information, wewill contact trial authors.
Data extraction and management
Two review authors (MP and JM) will independently extract trial
and outcome data from the selected trials using a data collection
form. If one of the review authors was involved in an included
trial, another review author will extract trial and outcome data
from this trial.
The review authors will extract the following data (according to the
Cochrane Handbook for Systematic Reviews of Interventions Table
7.3.a):
1. source;
2. eligibility;
3. participants (important imbalances in prognostic factors at
baseline, country, number of participants, age, gender, inclusion
and exclusion criteria, educational background, socioeconomic
status, cognition, pre-existing neurological impairment(s),
neurological history);
4. interventions;
5. outcomes and their time point of measurement;
6. comparison (details of interventions in treatment and
control groups, duration of treatment, details of co-intervention
in the groups;
7. results;
8. funding source and conflicts of interest among
investigators; and
9. miscellaneous.
Two review authors (MP and JM) will check the extracted data
for agreement. If they are not able to reach a consensus, a third
review author will arbitrate.
If necessary, the review authors will contact trial authors for more
information. We will report the outcome of efforts to source miss-
ing data in the review.
One review author (JM) will enter data into the Cochrane author-
ing and statistical software ReviewManager 5 (RevMan) (RevMan
2012), and a second author (MP) will check the data entry.
Assessment of risk of bias in included studies
Two review authors (JK, MP) will independently assess the risk of
bias in the included trials according to the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011a).
We will use checklists to independently assess:
• methods of random sequence generation;
• methods of allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessors;
• incomplete outcome data (dropouts, use of an intention-to-
treat analysis (ITT));
• selective outcome reporting; and
• other sources of bias.
Our judgements will be “High risk of bias”, “Low risk of bias” or
“Unclear risk of bias”. We will use “Unclear” where there is too
little information, or when what happened in the study is known
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but the risk of bias is unclear. We will describe the agreement
between authors during the ’Risk of bias’ assessment, and we will
resolve disagreement by reaching consensus through discussion.
We will contact trialists for clarification and to request missing
information when necessary.
Measures of treatment effect
For all outcomes representing continuous data, wewill entermeans
and standard deviations. We will calculate a pooled estimate of
the mean difference (MD) with 95% confidence intervals (CI).
If studies assess the same outcome but measure it with different
scales, we will calculate standardised mean differences (SMD) in-
stead of MD (Higgins 2011b). For all binary outcomes, we will
calculate risk ratios (RR) with 95% CI. Where trials (or groups
within a trial) have no event, e.g. no adverse events, we will cal-
culate risk differences (RD) with 95% CI instead of RR. For all
statistical comparisons we will use RevMan.
Unit of analysis issues
According to guidance in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011c), we will use only the first
period of cross-over trials and analyse the data as a parallel group
trial.
Dealing with missing data
We will contact the relevant principal investigators in order to
retrieve missing data. We will report the results of these efforts in
the review.
Assessment of heterogeneity
We will use the Higgins and Thompson’s I2 statistic in order to
assess heterogeneity (Higgins 2002). The I2 statistic ranges from
0% to 100%, where 0% indicates that the size of effects, for ex-
ample MDs of different studies pooled, are consistent with each
other.
If we detect heterogeneity, we will attempt to explore the reasons
for it (for example, whether related to characteristics of the studies,
such as participants, risk of bias, year of study, or place of study).
Assessment of reporting biases
Wewill assess publication bias visually using RevMan funnel plots
if the review includes 10 or more studies. However, publication
bias is not the only cause of asymmetrical funnel plots.
Data synthesis
We will use a random-effects model, regardless of the level of het-
erogeneity foundwith the I2 statistic. Thus, in cases of heterogene-
ity, we will not violate the preconditions of a fixed-effect model
approach.
If the review includes more than one comparison, which cannot
be included in the same analysis, we will report the results for each
comparison separately.
Subgroup analysis and investigation of heterogeneity
We will conduct three subgroup analyses as follows.
1. Duration of illness or critical condition: acute/subacute phase
(first six months of initiated intervention) versus chronic phase
(illness of more than six months’ duration and interventions ini-
tiated accordingly).
2. Use of definitions of CIP and CIM: use of definitive definition
of CIP and CIM in studies versus use of probable definition.
3. Imbalance of prognostic factors at baseline (such as age, duration
of illness and duration of ventilation).
Wewill considermeta-regression as an extension to subgroup anal-
yses when there are more than 10 studies in a meta-analysis.
Sensitivity analysis
To test the robustness of results we will conduct a sensitivity anal-
ysis, removing studies at high or unclear risk of bias (for example,
high or unclear versus low risk of bias from method of randomi-
sation).
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A P P E N D I C E S
Appendix 1. MEDLINE (OvidSP) search strategy
Database: Ovid MEDLINE(R) <1946 to June Week 4 2013>
Search Strategy:
--------------------------------------------------------------------------------
1 randomized controlled trial.pt. (378039)
2 controlled clinical trial.pt. (88553)
3 randomized.ab. (275457)
4 placebo.ab. (149266)
5 drug therapy.fs. (1722456)
6 randomly.ab. (193185)
7 trial.ab. (287286)
8 groups.ab. (1239381)
9 or/1-8 (3208243)
10 exp animals/ not humans.sh. (3996981)
11 9 not 10 (2730505)
12 Polyneuropathies/ (4193)
13 Muscle Weakness/ (5472)
14 Rhabdomyolysis/ (4264)
15 Quadriplegia/ (6952)
16 Paresis/ (4918)
17 neuromuscular manifestation$1.tw. (88)
18 (polyneuropath$ or myopath$).tw. (28621)
19 polyneuromyopath$.tw. (38)
20 neuromuscular disorder$.tw. (3081)
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21 neuromuscular disease$.tw. (3989)
22 paresis.tw. (7490)
23 quadriplegia.tw. (2112)
24 weakness.tw. (33892)
25 neuromyopath$.tw. (344)
26 motor syndrome.tw. (172)
27 muscle function.tw. (6982)
28 muscle strength/ (8259)
29 (muscle strength or respiratory failure).tw. (29931)
30 or/12-29 (127024)
31 Intensive Care/ (14924)
32 Critical Illness/ (16281)
33 intensive care.tw. (81047)
34 critical$ ill$.tw. (27308)
35 ventilator weaning/ (2849)
36 respiration, artificial/ (38024)
37 or/31-36 (138468)
38 electric stimulation therapy/ or electrostimulation.mp. or (electric$ adj2 stimulation).tw. (59228)
39 ((leg or lower) adj2 (limb$ or extremit$)).tw. (60715)
40 38 and 39 (873)
41 exp Exercise/ (109120)
42 physical therapy modalities/ or physiotherap$.tw. or physical therap$.tw. (42309)
43 exp Exercise Therapy/ (29085)
44 Musculoskeletal Manipulations/ (893)
45 Occupational Therapy/ (9889)
46 recovery of function/ (30425)
47 “Activities of Daily Living”/ (49818)
48 strength training.mp. (2517)
49 muscle training.mp. (1264)
50 (physical adj5 rehabilitation).tw. (4999)
51 or/40-50 (251838)
52 11 and 30 and 37 and 51 (85)
C O N T R I B U T I O N S O F A U T H O R S
All authors contributed to the conception and design of the protocol and approved the protocol. All authors will be involved in all
stages of the review. JM will screen titles and abstracts of publications identified by the searches. MP and JM will extract trial and
outcome data from the selected trials and analyse outcome data. JK and MP will assess the risk of bias in included studies. All authors
will interpret the results.
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